FDA Panel Clears Merck Insomnia Drug At Lower Dose

Law360, New York (May 22, 2013, 7:50 PM EDT) -- A U.S. Food and Drug Administration advisory panel on Wednesday recommended the regulator approve Merck & Co. Inc.’s proposed insomnia drug suvorexant, but only at the lower of two suggested dosages, finding the drug was unsafe at a higher dose.

The recommendation, which is nonbinding, came at a public meeting of the FDA's peripheral and central nervous system drugs advisory committee, a 17-member panel made up of a number of outside medical experts. The panel, with an abstention, voted 12-4 that the drug was effective in...
To view the full article, register now.